Gene therapy patient care experts

Intake, coordination and follow-up for patients receiving gene and cell therapies, tracked across organ systems for years after dosing.

2 experts, updated 20 Oct 2026

What our gene therapy patient care experts do

Patient care for gene and cell therapy begins with screening candidates against the criteria written into the therapeutic protocol, then establishing a baseline across the organ systems the protocol touches: cognition, metabolic markers including insulin sensitivity and lipid balance, and muscle function. Dosing is coordinated with the treating clinicians inside the partner health system, who retain clinical responsibility. After dosing, the same baseline measures are repeated on a set schedule, and findings are fed back to the protocol teams at Triple Helix Science. The follow-up window is measured in years, not weeks.

How they work

What gene therapy patient care experts have to judge is whether a reading in one system is an isolated result or the first sign of something moving elsewhere, which is why Triple Helix Science monitors cognition, metabolism and muscle together rather than referring each to a separate specialty. The therapeutic protocols being followed are developed in house and held as proprietary intellectual property, so the people running follow-up can read a result against the mechanism it was meant to act on, whether that is autophagy, genomic stability, toxic protein accumulation or mitochondrial efficiency.

When to bring them in

Bringing in gene therapy patient care experts makes sense when a government or sovereign health system is preparing to dose patients and needs the pathway defined before the first candidate is screened, not after. It also applies where a dosed cohort is already being carried and long-term monitoring has no structure behind it. Triple Helix Science builds these pathways as institutional partnerships, which means the partner commits to follow-up over a horizon of years and to measuring healthspan outcomes rather than treatment events alone.

Media reaction

Preventative care and emerging health systems

"Healthcare is shifting from treating illness to preventing it, and that will transform patient outcomes and health systems alike. The biggest opportunity lies with governments in emerging economies building from scratch. Free of legacy infrastructure, they can deliver next-generation care at scale or become international hubs for treatment."
Dr Christopher JensenDr Christopher Jensen, Chief Operating Officer, Triple Helix Science20 Oct 2026
1 of 2

Questions about gene therapy patient care experts

The questions we get asked most about patient care, answered plainly.

What does a gene therapy patient care expert do?
A gene therapy patient care expert manages the whole pathway a patient follows around a gene or cell therapy: eligibility and intake, coordination between the treating clinicians and the protocol team, and structured follow-up that continues for years after dosing. At Triple Helix Science that follow-up covers several organ systems at once, on the view that decline in one system accelerates decline in others.
What is involved in setting up patient care for a gene therapy programme?
Setting up patient care for a gene therapy programme means writing intake and eligibility criteria into the protocol itself, agreeing consent and record keeping with the treating site, scheduling dosing, then running a monitoring schedule measured in years. Triple Helix Science develops proprietary, IP-protected therapeutic protocols, so the follow-up schedule is part of the protocol rather than something added once patients are already dosed.
How is gene therapy patient care judged to be working?
Gene therapy patient care is judged on healthspan, meaning years lived in good physical and cognitive health, rather than on a single endpoint at a single visit. The checkable signals are whether patients stay in follow-up across years and whether change is captured across cognition, metabolic markers and muscle function. Triple Helix Science reports a completed Phase 1 human trial showing reversal of dementia progression, a finding that depends on exactly that kind of longitudinal data.
Is gene therapy patient care the same as clinical trial coordination?
No. Clinical trial coordination is bounded by a protocol and ends when the last visit is recorded and the data set closes. Gene therapy patient care carries on past that point, through routine delivery inside a health system, with follow-up running for years after dosing. The two overlap on intake, consent and scheduling, and diverge on how long the relationship with the patient lasts.
When does an organisation need a gene therapy patient care expert?
A gene therapy patient care expert is needed once a protocol is moving toward dosing patients, particularly where a sovereign health system intends to deliver it at national scale and will be following those patients for years. A programme still at laboratory stage, with no patients dosed, needs protocol development first. Individual patients seeking treatment for themselves are not the route here, since Triple Helix Science partners with governments, health systems, universities and pharmaceutical organisations rather than direct to consumers.

Contact an expert

Get in touch with an expert on patient care for comment, an interview or a question.

Straight to the Triple Helix Science press team.